ArticlePharmacy (Basel, Switzerland)2020
Opioid Use Disorders in People Living with HIV/AIDS: A Review of Implications for Patient Outcomes, Drug Interactions, and Neurocognitive Disorders.
Article in Pharmacy (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 17 citations in OpenAlex.
- Treatment Initiation, Substance Use Trajectories, and the Social Determinants of Health in Persons Living With HIV Seeking Medication for Opioid Use Disorder.Substance abuse · 2023Trial
- Correlates of days of medication for opioid use disorder exposure among people living with HIV in Northern Vietnam.The International journal on drug policy · 2022Trial
- HIV Infection and Opioid Treatment Enable the Engraftment of Kaposi Sarcoma-Like Tumors Into Immunocompetent Mice.Journal of medical virology · 2026Article
- Interactions between long-acting antiretrovirals and opioids: a call for clinical awareness.Clinical microbiology reviews · 2026Review
- Circulating plasma protein biomarkers associated with risk of negative clinical outcomes in virally suppressed people with HIV receiving medications for opioid use disorder.Frontiers in molecular biosciences · 2026Article
- Relationship Between Opioid Use, Depression, and Quality of Life Among Persons With HIV at End of Life.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort.The Journal of antimicrobial chemotherapy · 2025Article
- Medications for OUD: Extended-Release Naltrexone.Current addiction reports · 2025Article
- Mu opioid receptor activation in microglia enhances HIV-1 infection and HIV-infection-induced inflammatory responses.Frontiers in immunology · 2025Article
- Implementation of Injectable Cabotegravir/Rilpivirine for Treatment of Human Immunodeficiency Virus in Patients With Substance Use Disorders at a Syringe Exchange Clinic.Open forum infectious diseases · 2024Article
- Incarceration history and opioid use among adults living with HIV and chronic pain: a secondary analysis of a prospective cohort study.Health & justice · 2024Article
- Opioid misuse among people with HIV: results from the National Survey on Drug Use and Health (NSDUH) 2015-2019.Pain management · 2024Article
- HIV Prevalence and HIV Screening History Among a Veterans Association Cohort of People with Opioid and Alcohol Use Disorders.Journal of general internal medicine · 2024Article
- Provider perspectives on screening and treatment for opioid use disorder and mental health in HIV care: A qualitative study.PloS one · 2024Article
- The Synthetic Opioid Fentanyl Increases HIV Replication and Chemokine Co-Receptor Expression in Lymphocyte Cell Lines.Viruses · 2023Article
- HIV, opioid use, and alterations to the gut microbiome: elucidating independent and synergistic effects.Frontiers in immunology · 2023Review
- Importance of pharmacist-patient relationship in people living with HIV and concomitant opioid use disorder.Exploratory research in clinical and social pharmacy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The opioid epidemic has had a significant, negative impact in the United States, and people living with HIV/AIDS (PLWHA) represent a vulnerable sub-population that is at risk for negative sequela from prolonged opioid use or opioid use disorder (OUD). PLWHA are known to suffer from HIV-related pain and are commonly treated with opioids, leading to subsequent addictive disorders. PLWHA and OUD are at an increased risk for attrition in the HIV care continuum, including suboptimal HIV laboratory testing, delayed entry into HIV care, and initiation or adherence to antiretroviral therapy. Barriers to OUD treatment, such as medication-assisted therapy, are also apparent for PLWHA with OUD, particularly those living in rural areas. Additionally, PLWHA and OUD are at a high risk for serious drug-drug interactions through antiretroviral-opioid metabolic pathway-related inhibition/induction, or via the human ether-a-go-go-related gene potassium ion channel pathways. HIV-associated neurocognitive disorders can also be potentiated by the off-target inflammatory effects of opioid use. PLWHA and OUD might require more intensive, individualized protocols to sustain treatment for the underlying opioid addiction, as well as to provide proactive social support to aid in improving patient outcomes. Advancements in the understanding and management of PLWHA and OUD are needed to improve patient care. This review describes the effects of prescription and non-prescription opioid use in PLWHA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.